Castle Creek Biosciences, Inc.
https://castlecreekbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Castle Creek Biosciences, Inc.
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Deal Watch: Bristol, Pfizer Lead Off J.P. Morgan Week With Two Deals Apiece
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Castle Creek Pharmaceutical LLC
- Fibrocell Science, Inc.
- Paragon Biosciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice